Athanor Capital, LP Chemo Centryx, Inc. Transaction History

Athanor Capital, LP

$24.6 Million
Q4 2022

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $69,939 - $371,067	-7,293 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $553,349 - $764,164	-11,172 Reduced 60.5%	7,293 $374,000
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $383,055 - $528,252	8,107 Added 78.27%	18,465 $1.14 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $895,852 - $1.19 Million	-19,328 Reduced 65.11%	10,358 $568,000
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $1.15 Million - $1.93 Million	29,686 New	29,686 $1.71 Million
Q1 2020 May 14, 2020	SELL	$32.73 - $50.78 $1.06 Million - $1.65 Million	-32,434 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $220,875 - $1.28 Million	32,434 New	32,434 $1.28 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Athanor Capital, LP with notifications on news.